Patent review of cannabinoid receptor type 2 (CB₂R) modulators (2016-present)

References

• Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res. 2011 Apr 01;50(2):193–211. doi: 10.1016/j.plipres.2011.01.001
   PubMed Web of Science ®Google Scholar
• Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2020 Jan;16(1):9–29. doi: 10.1038/s41582-019-0284-z
   PubMed Web of Science ®Google Scholar
• Maccarrone M. Missing pieces to the endocannabinoid puzzle. Trends Mol Med. 2020 Mar;26(3):263–272. doi: 10.1016/j.molmed.2019.11.002
   PubMed Web of Science ®Google Scholar
• Devane WA, Dysarz FA, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat-brain. Mol Pharmacol. 1988 Nov;34(5):605–613.
   PubMed Web of Science ®Google Scholar
• Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86(8):1646±. doi: 10.1021/ja01062a046
   Web of Science ®Google Scholar
• Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992 Dec 18;258(5090):1946–1949. doi: 10.1126/science.1470919
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abushaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993 Sep 2;365(6441):61–65. doi: 10.1038/365061a0
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Benshabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995 Jun 29;50(1):83–90. doi: 10.1016/0006-2952(95)00109-D
   PubMed Web of Science ®Google Scholar
• Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor-ligand in brain. Biochem Biophys Res Commun. 1995 Oct 4;215(1):89–97. doi: 10.1006/bbrc.1995.2437
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: ‘killing two birds with one stone’. Prostaglandins Leukot Essent Fatty Acids. 1995 Jul;53(1):1–11. doi: 10.1016/0952-3278(95)90077-2
   PubMed Web of Science ®Google Scholar
• Chicca A, Arena C, Manera C. Beyond the direct activation of cannabinoid receptors: new strategies to modulate the endocannabinoid system in CNS-related diseases. Recent Pat CNS Drug Discov. 2016;10(2):122–141. doi: 10.2174/1574889810999160603185126
   PubMedGoogle Scholar
• Maccarrone M, Di Marzo V, Gertsch J, et al. Goods and bads of the Endocannabinoid System as a therapeutic target: lessons learned after 30 years. Pharmacol Rev. 2023 Sep;75(5):885–958. doi: 10.1124/pharmrev.122.000600
   PubMed Web of Science ®Google Scholar
• Pacher P, Kogan NM, Mechoulam R. Beyond THC and endocannabinoids. Annu Rev Pharmacol Toxicol. 2020 Jan 6;60(1):637–659. doi: 10.1146/annurev-pharmtox-010818-021441
   PubMedGoogle Scholar
• Maccarrone M, Bab R, Biro T, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015 May;36(5):277–296. doi: 10.1016/j.tips.2015.02.008
   PubMed Web of Science ®Google Scholar
• Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002 Jun;54(2):161–202. doi: 10.1124/pr.54.2.161
   PubMed Web of Science ®Google Scholar
• Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006 Sep;58(3):389–462. doi: 10.1124/pr.58.3.2
   PubMed Web of Science ®Google Scholar
• Bouaboula M, Rinaldi M, Carayon P, et al. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem. 1993 May 15;214(1):173–180. doi: 10.1111/j.1432-1033.1993.tb17910.x
   PubMedGoogle Scholar
• Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995 Aug 15;232(1):54–61. doi: 10.1111/j.1432-1033.1995.tb20780.x
   PubMedGoogle Scholar
• Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol. 2010 Jun;160(3):467–479. doi: 10.1111/j.1476-5381.2010.00729.x
   PubMed Web of Science ®Google Scholar
• Mallat A, Teixeira-Clerc F, Lotersztajn S. Cannabinoid signaling and liver therapeutics. J Hepatol. 2013 Oct;59(4):891–896. doi: 10.1016/j.jhep.2013.03.032
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Rajesh M, Pan H, et al. Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med. 2010 Feb 1;48(3):457–467. doi: 10.1016/j.freeradbiomed.2009.11.022
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Pan H, Rajesh M, et al. CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br J Pharmacol. 2010 Jun;160(3):657–668. doi: 10.1111/j.1476-5381.2010.00769.x
   PubMed Web of Science ®Google Scholar
• Atwood BK, Wager-Miller J, Haskins C, et al. Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. Mol Pharmacol. 2012 Feb;81(2):250–263. doi: 10.1124/mol.111.074013
   PubMed Web of Science ®Google Scholar
• Ofek O, Karsak M, Leclerc N, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA. 2006 Jan 17;103(3):696–701. doi: 10.1073/pnas.0504187103
   PubMed Web of Science ®Google Scholar
• Cabral GA, Raborn ES, Griffin L, et al. CB2 receptors in the brain: role in central immune function. Br J Pharmacol. 2008 Jan;153(2):240–251. doi: 10.1038/sj.bjp.0707584
   PubMed Web of Science ®Google Scholar
• Marchalant Y, Brownjohn PW, Bonnet A, et al. Validating antibodies to the Ccannabinoid CB2 receptor: antibody sensitivity is not evidence of antibody specificity. J Histochem Cytochem. 2014 Jun;62(6):395–404. doi: 10.1369/0022155414530995
   PubMed Web of Science ®Google Scholar
• Soethoudt M, Grether U, Fingerle J, et al. Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nat Commun. 2017 Jan 03;8(1):13958. doi: 10.1038/ncomms13958
   PubMedGoogle Scholar
• Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005 Oct 14;310(5746):329–332. doi: 10.1126/science.1115740
   PubMed Web of Science ®Google Scholar
• Xi ZX, Peng XQ, Li X, et al. Brain cannabinoid CB(2) receptors modulate cocaine’s actions in mice. Nat Neurosci. 2011 Jul 24;14(9):1160–1166. doi: 10.1038/nn.2874
   PubMed Web of Science ®Google Scholar
• Navarrete F, Rodriguez-Arias M, Martin-Garcia E, et al. Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine. Neuropsychopharmacology. 2013 Nov;38(12):2515–2524. doi: 10.1038/npp.2013.157
   PubMed Web of Science ®Google Scholar
• Aymerich MS, Aso E, Abellanas MA, et al. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. Biochem Pharmacol. 2018 Nov;157:67–84. doi: 10.1016/j.bcp.2018.08.016
   PubMed Web of Science ®Google Scholar
• Kleyer J, Nicolussi S, Taylor P, et al. Cannabinoid receptor trafficking in peripheral cells is dynamically regulated by a binary biochemical switch. Biochem Pharmacol. 2012 May 15;83(10):1393–1412. doi: 10.1016/j.bcp.2012.02.014
   PubMed Web of Science ®Google Scholar
• Brailoiu GC, Deliu E, Marcu J, et al. Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors. Biochemistry-Us. 2014 Aug 5;53(30):4990–4999. doi: 10.1021/bi500632a
   PubMed Web of Science ®Google Scholar
• Castaneda JT, Harui A, Roth MD. Regulation of cell surface CB(2) receptor during human B Cell activation and differentiation. J Neuroimmune Pharmacol. 2017 Sep;12(3):544–554. doi: 10.1007/s11481-017-9744-7
   PubMed Web of Science ®Google Scholar
• Oyagawa CRM, de la Harpe SM, Saroz Y, et al. Cannabinoid receptor 2 signalling bias elicited by 2,4,6-trisubstituted 1,3,5-triazines. Front Pharmacol. 2018;9:1202. doi: 10.3389/fphar.2018.01202
   PubMed Web of Science ®Google Scholar
• Kishimoto S, Muramatsu M, Gokoh M, et al. Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J Biochem. 2005 Feb;137(2):217–223. doi: 10.1093/jb/mvi021
   PubMed Web of Science ®Google Scholar
• Borner C, Smida M, Hollt V, et al. Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. J Biol Chem. 2009 Dec 18;284(51):35450–35460. doi: 10.1074/jbc.M109.006338
   PubMed Web of Science ®Google Scholar
• Ziring D, Wei B, Velazquez P, et al. Formation of B and T cell subsets require the cannabinoid receptor CB2. Immunogenetics. 2006 Sep;58(9):714–725. doi: 10.1007/s00251-006-0138-x
   PubMed Web of Science ®Google Scholar
• Cencioni MT, Chiurchiu V, Catanzaro G, et al. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One. 2010 Jan 14;5(1):e8688. doi: 10.1371/journal.pone.0008688
   PubMed Web of Science ®Google Scholar
• Correa F, Hernangomez-Herrero M, Mestre L, et al. The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. Brain Behav Immun. 2011 May;25(4):736–749. doi: 10.1016/j.bbi.2011.01.020
   PubMed Web of Science ®Google Scholar
• Hegde VL, Hegde S, Cravatt BF, et al. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol Pharmacol. 2008 Jul;74(1):20–33. doi: 10.1124/mol.108.047035
   PubMed Web of Science ®Google Scholar
• Pacher P, Mukhopadhyay P, Mohanraj R, et al. Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension. 2008 Oct;52(4):601–607. doi: 10.1161/HYPERTENSIONAHA.105.063651
   PubMed Web of Science ®Google Scholar
• Pacher P, Steffens S. The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol. 2009 Jun;31(1):63–77. doi: 10.1007/s00281-009-0145-8
   PubMed Web of Science ®Google Scholar
• Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol. 2008 Jan;153(2):263–270. doi: 10.1038/sj.bjp.0707486
   PubMed Web of Science ®Google Scholar
• Wright K, Rooney N, Feeney M, et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology. 2005 Aug;129(2):437–453. doi: 10.1016/j.gastro.2005.05.026
   PubMed Web of Science ®Google Scholar
• Izzo AA, Camilleri M. Cannabinoids in intestinal inflammation and cancer. Pharmacol Res. 2009 Aug;60(2):117–125. doi: 10.1016/j.phrs.2009.03.008
   PubMed Web of Science ®Google Scholar
• Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010 Apr;126(1):21–38. doi: 10.1016/j.pharmthera.2009.12.005
   PubMed Web of Science ®Google Scholar
• Mallat A, Lotersztajn S. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G9–G12. doi: 10.1152/ajpgi.00467.2007
   PubMed Web of Science ®Google Scholar
• Pacher P, Gao B. Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases. Am J Physiol Gastrointest Liver Physiol. 2008 Apr;294(4):G850–4. doi: 10.1152/ajpgi.00523.2007
   PubMed Web of Science ®Google Scholar
• Matyas C, Erdelyi K, Trojnar E, et al. Interplay of liver-heart inflammatory axis and cannabinoid 2 receptor signaling in an experimental model of hepatic cardiomyopathy. Hepatology. 2020 Apr;71(4):1391–1407. doi: 10.1002/hep.30916
   PubMed Web of Science ®Google Scholar
• Horvath B, Magid L, Mukhopadhyay P, et al. A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury. Br J Pharmacol. 2012 Apr;165(8):2462–2478. doi: 10.1111/j.1476-5381.2011.01381.x
   PubMed Web of Science ®Google Scholar
• Zoja C, Locatelli M, Corna D, et al. Therapy with a selective cannabinoid receptor type 2 agonist limits albuminuria and renal injury in mice with type 2 diabetic nephropathy. Nephron. 2016;132(1):59–69. doi: 10.1159/000442679
   PubMed Web of Science ®Google Scholar
• Trojnar E, Erdelyi K, Matyas C, et al. Cannabinoid-2 receptor activation ameliorates hepatorenal syndrome. Free Radic Biol Med. 2020 May 20;152:540–550. doi: 10.1016/j.freeradbiomed.2019.11.027
   PubMed Web of Science ®Google Scholar
• Centonze D, Finazzi-Agro A, Bernardi G, et al. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci. 2007 Apr;28(4):180–187. doi: 10.1016/j.tips.2007.02.004
   PubMed Web of Science ®Google Scholar
• Fernandez-Ruiz J, Romero J, Velasco G, et al. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci. 2007 Jan;28(1):39–45. doi: 10.1016/j.tips.2006.11.001
   PubMed Web of Science ®Google Scholar
• Fernandez-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol. 2009 Apr;156(7):1029–1040. doi: 10.1111/j.1476-5381.2008.00088.x
   PubMed Web of Science ®Google Scholar
• Garcia-Martin A, Garrido-Rodriguez M, Navarrete C, et al. Cannabinoid derivatives acting as dual PPARgamma/CB2 agonists as therapeutic agents for systemic sclerosis. Biochem Pharmacol. 2019 May;163:321–334. doi: 10.1016/j.bcp.2019.02.029
   PubMed Web of Science ®Google Scholar
• Spiera R, Kuwana M, Khanna D, et al. Efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in a phase 3 randomized trial in diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 2023 Sep;75(9):1608–1618. doi: 10.1002/art.42510
   PubMed Web of Science ®Google Scholar
• Jiang BE, Jiang X, Zhang Q, et al. From a designer drug to the discovery of selective cannabinoid type 2 receptor agonists with favorable pharmacokinetic profiles for the treatment of systemic sclerosis. J Med Chem. 2021 Jan 14;64(1):385–403. doi: 10.1021/acs.jmedchem.0c01023
   PubMed Web of Science ®Google Scholar
• Jiang X, Chen S, Zhang Q, et al. Celastrol is a novel selective agonist of cannabinoid receptor 2 with anti-inflammatory and anti-fibrotic activity in a mouse model of systemic sclerosis. Phytomedicine. 2020 Feb;67:153160. doi: 10.1016/j.phymed.2019.153160
   PubMed Web of Science ®Google Scholar
• Gruden G, Barutta F, Kunos G, et al. Role of the endocannabinoid system in diabetes and diabetic complications. Br J Pharmacol. 2016 Apr;173(7):1116–1127. doi: 10.1111/bph.13226
   PubMed Web of Science ®Google Scholar
• Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabinoid receptor 2 activation alleviates diabetes-induced cardiac dysfunction, inflammation, oxidative stress, and fibrosis. Geroscience. 2022 Jun;44(3):1727–1741. doi: 10.1007/s11357-022-00565-9
   PubMed Web of Science ®Google Scholar
• Jourdan T, Szanda G, Rosenberg AZ, et al. Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy. Proc Natl Acad Sci USA. 2014 Dec 16;111(50):E5420–8. doi: 10.1073/pnas.1419901111
   PubMed Web of Science ®Google Scholar
• Rajesh M, Batkai S, Kechrid M, et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes. 2012 Mar;61(3):716–727. doi: 10.2337/db11-0477
   PubMed Web of Science ®Google Scholar
• El-Remessy AB, Rajesh M, Mukhopadhyay P, et al. Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line. Diabetologia. 2011 Jun;54(6):1567–1578. doi: 10.1007/s00125-011-2061-4
   PubMed Web of Science ®Google Scholar
• Spyridakos D, Mastrodimou N, Vemuri K, et al. Blockade of CB1 or activation of CB2 cannabinoid receptors is differentially efficacious in the treatment of the early pathological events in streptozotocin-induced diabetic rats. Int J Mol Sci. 2022 Dec 23;24(1):240. doi: 10.3390/ijms24010240
   PubMed Web of Science ®Google Scholar
• Barutta F, Piscitelli F, Pinach S, et al. Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes. 2011 Sep;60(9):2386–2396. doi: 10.2337/db10-1809
   PubMed Web of Science ®Google Scholar
• Barutta F, Corbelli A, Mastrocola R, et al. Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes. 2010 Apr;59(4):1046–1054. doi: 10.2337/db09-1336
   PubMed Web of Science ®Google Scholar
• Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol. 2008 Jan;153(2):319–334. doi: 10.1038/sj.bjp.0707531
   PubMed Web of Science ®Google Scholar
• Anand P, Whiteside G, Fowler CJ, et al. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev. 2009 Apr;60(1):255–266. doi: 10.1016/j.brainresrev.2008.12.003
   PubMedGoogle Scholar
• Thakur GA, Tichkule R, Bajaj S, et al. Latest advances in cannabinoid receptor agonists. Expert Opin Ther Pat. 2009 Dec;19(12):1647–1673. doi: 10.1517/13543770903436505
   PubMed Web of Science ®Google Scholar
• Riether D. Selective cannabinoid receptor 2 modulators: a patent review 2009–present. Expert Opin Ther Pat. 2012 May;22(5):495–510. doi: 10.1517/13543776.2012.682570
   PubMed Web of Science ®Google Scholar
• Han S, Chen JJ, Chen JZ. Latest progress in the identification of novel synthetic ligands for the cannabinoid CB2 receptor. Mini Rev Med Chem. 2014 May;14(5):426–443. doi: 10.2174/1389557514666140428105753
   PubMed Web of Science ®Google Scholar
• Han S, Thatte J, Buzard DJ, et al. Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. J Med Chem. 2013 Nov 14;56(21):8224–8256. doi: 10.1021/jm4005626
   PubMed Web of Science ®Google Scholar
• Morales P, Hernandez-Folgado L, Goya P, et al. Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update. Expert Opin Ther Pat. 2016 Jul;26(7):843–856. doi: 10.1080/13543776.2016.1193157
   PubMed Web of Science ®Google Scholar
• Aghazadeh Tabrizi M, Baraldi PG, Borea PA, et al. Medicinal chemistry, pharmacology, and potential therapeutic benefits of cannabinoid CB2 receptor agonists. Chem Rev. 2016 Jan 27;116(2):519–560. doi: 10.1021/acs.chemrev.5b00411
   PubMed Web of Science ®Google Scholar
• Manera C, Arena C, Chicca A. Synthetic cannabinoid receptor agonists and antagonists: implication in CNS disorders. Recent Pat CNS Drug Discov. 2016;10(2):142–156. doi: 10.2174/1574889810666160519113853
   PubMedGoogle Scholar
• Cooper A, Singh S, Hook S, et al. Chemical tools for studying lipid-binding class a G protein-coupled receptors. Pharmacol Rev. 2017 Jul;69(3):316–353. doi: 10.1124/pr.116.013243
   PubMed Web of Science ®Google Scholar
• Brennecke B, Gazzi T, Atz K, et al. Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010. Pharm Pat Anal. 2021;10(3):111–163. doi: 10.4155/ppa-2021-0002
   PubMed Web of Science ®Google Scholar
• Guba W, Nazaré M, Grether U. Natural compounds and synthetic drugs to target type-2 Cannabinoid (CB2) Receptor. In: Maccarrone M, editor. New tools to interrogate endocannabinoid signalling: from natural compounds to synthetic drugs. Thomas Graham House, Cambridge: The Royal Society of Chemistry; 2020. p. 89–167.
   Google Scholar
• Bell MR, D’Ambra TE, Kumar V, et al. Antinociceptive (aminoalkyl)indoles. J Med Chem. 1991 Mar;34(3):1099–1110. doi: 10.1021/jm00107a034
   PubMed Web of Science ®Google Scholar
• Rinaldi M, Barth F, Casellas P, et al., inventors; SANOFI SA, assignee. Utilisation De Composes Agonistes Du Recepteur Cb2 Humain Pour La Preparation De Medicaments Immunomodulateurs, Nouveaux Composes Agonistes Du Recepteur Cb2 Et Les Compositions Pharmaceutiques Les Contenant. FR patent FR 2735774 A1. 1996 [1995 Jun 21].
   Google Scholar
• Marsicano G, Lutz B. Neuromodulatory functions of the endocannabinoid system. J Endocrinol Invest. 2006;29(3 Suppl):27–46.
   PubMedGoogle Scholar
• De Laurentiis A, Araujo HA, Rettori V. Role of the endocannabinoid system in the neuroendocrine responses to inflammation. Curr Pharm Des. 2014;20(29):4697–4706. doi: 10.2174/1381612820666140130212957
   PubMed Web of Science ®Google Scholar
• Citeline Informa Pharma Intelligence [data base]. (NY) City (NY): Norstella; [cited 2023 Oct]; Available from: http://www.citeline.com/
   Google Scholar
• Clarivate CortellisTM [data base]. London (UK): Clarivate; [cited 2023 Oct]; Available from: https://access.clarivate.com
   Google Scholar
• Adis Insight Web Page [Internet]. Cham (SZ): Springer; [cited 2023 Oct]; Available from: https://adisinsight.springer.com/drugs/800027102
   Google Scholar
• Adis Insight Web Page [Internet]. Drug Report on Nabilone]. Cham (SZ): Springer; [cited 2023 Oct]. Available from: https://adisinsight.springer.com/drugs/800025856
   Google Scholar
• Cannabidiol Dublin, Ireland: jazz Pharmaceuticals. 2023 Sep. Available from: https://www.jazzpharma.com/medicines/our-medicines/
   Google Scholar
• Clarivate CortellisTM [data base]. Drug Report on Cannabidiol. London (UK): Clarivate; [cited 2023 Oct]. Available from: http://access.clarivate.com/login?app=cortellis
   Google Scholar
• Adis Insight Web Page [Internet]. Drug report on lenabasum. Cham (SZ): Springer; [cited 2023 Jan]. Available from: https://adisinsight.springer.com/drugs/800007180
   Google Scholar
• Lenabasum Norwood (MA): Corbus Pharmaceuticals Inc.; [cited 2022 Oct]. Available from: www.corbuspharma.com
   Google Scholar
• Adis Insight Web Page [Internet]. Cham (SZ): Springer; [cited 2022 Oct]; Available from: https://adisinsight.springer.com/drugs/800039670
   Google Scholar
• ANZCTR Web Page [Internet]. The Australian New Zealand Clinical Trials Registry. ACTRN12616001435471, CMX-20]. Available from Camperdown (AU); [cited 2023 Oct]. Available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371547&isReview=true
   Google Scholar
• Clarivate CortellisTM [data base]. Drug Report on CMX-020. London (UK): Clarivate; [cited 2023 Oct]. Available from: https://access.clarivate.com/login?app=cortelliis
   Google Scholar
• Grether U. First disclosure of cannabinoid receptor type 2 agonist RG7774 – an innovative oral treatment for diabetic retinopathy XXVII EFMC International Symposium on Medicinal Chemistry. Nice (FR); 2022. https://efmc-ismc2022.ldorganisation.com/programme
   Google Scholar
• Clarivate CortellisTM [data base]. Drug Report on RG7774. London (UK): Clarivate; [cited 2023 Oct]. Available from: https://access.clarivate.com/login?app=cortellis
   Google Scholar
• ART27.13. Solana Beach (CA): Artelo Biosciences; [cited 2023 Oct]. Available from: https://artelobio.com/pipeline/
   Google Scholar
• ClinicalTrials.gov [Internet]. NCT05525455, TT-816 as Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88); 2022 Aug 29]. Bethesda (MD): National Library of Medicine, US; 2000 Feb 29 [cited 2023 Dec 30]. Available from: https://clinicaltrials.gov/study/NCT05525455?term=NCT05525455&rank=1
   Google Scholar
• Citeline Informa Pharma Intelligence [data base]. Drug Profile of TT-816]. (NY) City (NY): Norstella; [cited 2023 Nov]. Available from: https://www.citeline.com/
   Google Scholar
• NTRX-07 Gates Mills, OH: NeuroTherapia, Inc. [cited 2023 Oct]. Available from: https://www.neurotherapia.com/research
   Google Scholar
• Clarivate CortellisTM [data base]. Drug report on NTRX-07]. London (UK): Clarivate; [cited 2023 Oct]. Available from: https://acccess.clarivate.com/login?app=cortellis
   Google Scholar
• CNTX-6016. Boston (MA): Centrexion Corporation; [cited 2023 Oct]. Available from: https://centrexion.com/science/pipeline/
   Google Scholar
• ClinicalTrials.gov [Internet]. NCT04857957, Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects with PDN]. Bethesda (MD): National Library of Medicine, US; 2000 Aug 29 [cited 2023 Oct]. Available from: https://clinicaltrials.gov/ct2/show/NCT04857957
   Google Scholar
• Adis Insight Web Page [Internet]. Drug Report on Onternabez. Cham (SZ): Springer; [cited 2023 Mar]. Available from: https://adisinsight.springer.com/drugs/800058029
   Google Scholar
• Han S, Thoresen L, Jung JK, et al. Discovery of APD371: identification of a highly potent and selective CB(2) agonist for the treatment of chronic pain. ACS Med Chem Lett. 2017 Dec 14;8(12):1309–1313. doi: 10.1021/acsmedchemlett.7b00396
   PubMed Web of Science ®Google Scholar
• Clarivate CortellisTM [data base]. Drug Report On Nabiximols]. London (UK): Clarivate; [cited 2023 Oct]. Available from: https://access.clarivatee.com/login?app=cortellis
   Google Scholar
• Citeline PharmaprojectsTM [data base]. (NY) City (NY): Norstella; [cited 2023 October]; Available from: https://www.ciiteline.com/
   Google Scholar
• Zurier RB, Rossetti RG, Lane JH, et al. Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum. 1998 Jan;41(1):163–170. doi: 10.1002/1529-0131(199801)41:1<163:AID-ART20>3.0.CO;2-9
   PubMedGoogle Scholar
• Spiera R, Kuwana M, Khanna D, et al. OP0171 Phase 3 Trial of Lenabasum, a CB2 agonist, for the treatment of diffuse cutaneous systemic sclerosis (DCSSC). Ann Rheumatic Dis. 2021;80(Suppl 1):102–103. doi: 10.1136/annrheumdis-2021-eular.1795
   Google Scholar
• Werth V, White B, Dgetluck N, et al. OP0162 Efficacy and safety of Lenabasum in the phase 3 determine trial in dermatomyositis. Ann Rheumatic Dis. 2022;81(Suppl 1):106–107. doi: 10.1136/annrheumdis-2022-eular.5037
   Google Scholar
• Attala Mohamed N, Diaz P, inventors; Univ Texas, Attala Mohamed Naguib, Diaz Philippe, assignee. Heterocyclic modulators of cannabinoid receptors. WO patent WO 2009/012221 A1. 2009 [2008 Jul 14.
   Google Scholar
• Attala Mohamed N, Diaz P, inventors; Cleveland Clinic Foundation, assignee. Heterocyclic modulators of cannabinoid receptors. US patent US 9339486 B2. 2016 [2015 Feb 2].
   Google Scholar
• Naguib M, Giordano T. A Novel Therapeutic (NTRX-07) targeting aeuroinflammation in alzheimer's disease is undergoing phase I trials. In: Presented at: Alzheimer’s Association International Conference 2019; Chicago (USA); 2019 Jul 22–26.
   Google Scholar
• ClinicalTrials.gov [Internet]. NCT04375436, Safety and Tolerability of NTRX-07 in Healthy Volunteers. Bethesda (MD): National Library of Medicine, US; 2000 Feb 29 [cited 2023 Oct]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT04375436
   Google Scholar
• Foss J, Naguib M, Giordano T. Conference Poster – a Phase I Single Ascending Dose Safety Study of NTRX-07. In: Normal Volunteers Alzheimer’s Association International Conference (AAIC); Amsterdam, Netherlands. NeuroTherapia, Inc; 2020. Available from: https://alz.confex.com/alz/20amsterdam/meetingapp.cgi/Paper/39150
   Google Scholar
• Yates A, Dickinson P, Ward R, inventors; Artelo Biosciences Ltd, assignee. Pharmaceutical Compositions Comprising Cannabinoid Agonist. WO patent WO 2022/123233 A1. 2022 [2021 Dec 7].
   Google Scholar
• Kaur H, Liu X, Nepal P, et al. inventors; Tetra Bio Pharma Inc, assignee. Methods, processes, and compositions for improved preparation of HU308 and HU433. WO patent WO 2022/061461 A1. 2022 [2021 Sep 23].
   Google Scholar
• Kaur H, Farooq H, Thirunavukarasu S, et al., inventors; Tetra Bio Pharma Inc, assignee. Parenteral cannabinoid formulations and uses thereof. WO patent WO 2022/133612 A1. 2022 [2021 Dec 23.
   Google Scholar
• Citeline Informa Pharma Intelligence [data base]. Drug Profile of Etrinabdione]. (NY) City (NY): Norstella; [cited 2023 Oct]. Available from: https://www.citeline.com//
   Google Scholar
• Clarivate CortellisTM [data base]. London (UK): Clarivate; [cited 2023 Oct]; Available from: https://accesss.clarivate.com/login?app=cortellis
   Google Scholar
• Clarivate CortellisTM [data base]. Drug Report On S-777469. London (UK): Clarivate; [cited 2023 Oct]. Available from: https:///access.clarivate.com/login?app=cortellis
   Google Scholar
• Shionogi, Co L. 1st Quarter of Fiscal 2009 Conference Call. 2009 Aug 3 [cited 2022 Oct]. Available from: https://www.shionogi.com/content/dam/shionogi/global/investors/pdf/e_p090803.pdf
   Google Scholar
• Clarivate CortellisTM [data base]. London (UK): Clarivate; [cited 2023 Oct]; Available from: https://access.clarivate.com/logiin?app=cortellis
   Google Scholar
• Clarivate CortellisTM [data base]. London (UK): Clarivate; [cited 2023 Oct]; Available from: https://access.clarivate.com/login?appp=cortellis
   Google Scholar
• Ding Z, Zhang Bei B, inventors; Lilly Co Eli, Lilly China Res And Dev Co Ltd, assignee. Treatment for nonalcoholic steatohepatitis and fibrosis. WO patent WO 2017/184413 A1. 2017 Apr 13.
   Google Scholar
• Hohmann Andrea G, Mackie Ken P, Lin X, et al. inventors; Univ Indiana Res & Tech Corp, assignee. Methods of using cannabinoid cb2 receptor agonist compositions to suppress and prevent opioid tolerance and withdrawal in a subject. US patent US 2019/0314379 A1. 2019 Jan 24.
   Google Scholar
• Omeara Jeffrey A, To Quang HUY, inventors; CAnopy Growth Corp, assignee. Cannabinoid derivatives. WO patent WO 2021/000053 A1. 2021 2020/07/03.
   Google Scholar
• Omeara Jeffrey A, To Quang HUY, inventors; Canopy Growth Corp, assignee. Cannabinoid derivatives. WO patent WO 2021/000054 A1. 2021 [2020 Jul 3.
   Google Scholar
• Siawash A, Ave E Tomntca L, Alan OJ, et al. inventors; Cannabinoid derivatives | dérivés cannabinoïdes dérivés cannabinoïdes cannabinoid derivatives. WO patent WO2021007660A1. 2021.
   Google Scholar
• Omeara Jeffrey A, To Quang HUY, inventors; Canopy Growth Corp, assignee. Cannabinoid derivatives. WO patent WO 2021/113958 A1. 2021 [2020 Nov 27].
   Google Scholar
• Gunning Patrick T, Omeara Jeffrey A, To Quang HUY, et al. Cannabinoid derivatives. WO patent WO 2021/113959 A1. 2021 [2020 Nov 27].
   Google Scholar
• Alan OJ, Pond Drive Hholgsca M, Werner PH, et al. inventors; Cannabinoid derivatives | dérivés cannabinoïdes dérivés cannabinoïdes cannabinoid derivatives. WO patent WO2021007662A1. 2021.
   Google Scholar
• Walji AM, Sanchez RI, Clas S-D, et al. Discovery of MK-8970: an acetal carbonate prodrug of raltegravir with enhanced colonic absorption. ChemMedchem. 2015;10(2):245–252. doi: 10.1002/cmdc.201402393
   PubMed Web of Science ®Google Scholar
• Heidel KM, Dowd CS. Phosphonate prodrugs: an overview and recent advances. Future Med Chem. 2019 Jul;11(13):1625–1643. doi: 10.4155/fmc-2018-0591
   PubMed Web of Science ®Google Scholar
• Geiling BEN, Hajirahimkhan S, Jackowetz John N, et al. inventors; Canopy Growth Corp, assignee. Water-soluble formulations of cannabinoids or cannabis-derived compounds, methods of making and use. WO patent WO 2020/107114 A1. 2020 [2019 Nov 27].
   Google Scholar
• Adair C, Geiling BEN, Manjili Mohammadmehdi H, et al. inventors; Canopy Growth Corp, assignee. Compositions comprising a cannabinoid or a cannabis-derived compound, methods of making and use. WO patent WO 2020/107119 A1. 2020 [2019 Nov 28.
   Google Scholar
• Ahmar S, Omeara Jeffrey A, inventors; Canopy Growth Corp, assignee. Cannabinoid derivatives. WO patent WO 2021/007659 A1. 2021 [2020 Jul 10].
   Google Scholar
• Ahmar S, Omeara Jeffrey A, inventors; Canopy Growth Corp, assignee. Cannabinoid derivatives. WO patent WO 2021/007661 A1. 2021 [2020 Jul 10].
   Google Scholar
• Ahmar S, Omeara Jeffrey A, Dove Peter M inventors; Canopy Growth Corp, assignee. Cannabinoid derivatives. WO patent WO 2021/102569 A1. 2021 [2020 Nov 25].
   Google Scholar
• Ahmar S, Kim Jung YUN, Lai Ping S, et al. inventors; Canopy Growth Corp, assignee. Cannabinoid derivatives. WO patent WO 2021/102568 A1. 2021 [2020 Nov 25].
   Google Scholar
• Ahmar S, Kim Jung YUN, Lai Ping S, et al. inventors; Canopy Growth Corp, assignee. Cannabinoid derivatives. WO patent WO 2021/062557 A1. 2021 [2020 Oct 2].
   Google Scholar
• Ahmar S, Kim Jung YUN, Lai Ping S, et al. inventors; Canopy Growth Corp, assignee. Cannabinoid derivatives. WO patent WO 2021/062559 A1. 2021 [2020 Oct 2].
   Google Scholar
• Ahmar S, Gnanasekaran Krishna K, Omeara Jeffrey A, inventors; Canopy Growth Corp, assignee. Cannabigerol derivatives and use thereof as cannabinoid receptor modulators. WO patent WO 2021/102567 A1. 2021 [2020 Nov 25].
   Google Scholar
• Ahmar S, Gnanasekaran Krishna K, Omeara Jeffrey A, et al. inventors; Canopy Growth Corp, assignee. Cannabinoid derivatives. WO patent WO 2021/007663 A1. 2021 [2020 Jul 10].
   Google Scholar
• Gobbi L, Grether UWE, Kretz J, et al., inventors; Hoffmann La Roche, Eth Zuerich, assignee. novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2. WO patent WO 2020/002320 A1. 2020 [2019 Jun 25].
   Google Scholar
• Ametamey Simon M, Atz K, Gobbi L, et al., inventors; Hoffmann La Roche, Eidgenoessische Technische Hochschule Zuerich, assignee. Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists. WO patent WO 2020/002270 A1. 2020 [2019 Jun 25].
   Google Scholar
• Ametamey Simon M, Gobbi L, Grether UWE, et al., inventors; Hoffmann La Roche, Eidgenoessische Technische Hochschule Zuerich, assignee. Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2. WO patent WO 2020/002280 A1. 2020 [2019 Jun 25].
   Google Scholar
• Haider A, Kretz J, Gobbi L, et al. Structure-activity relationship studies of pyridine-based ligands and identification of a fluorinated derivative for positron emission tomography imaging of cannabinoid type 2 receptors. J Med Chem. [2019 Dec 26];62(24):11165–11181. doi: 10.1021/acs.jmedchem.9b01280
   PubMed Web of Science ®Google Scholar
• Ametamey Simon M, Gobbi L, Grether UWE, et al., inventors; Hoffmann La Roche, Eth Zuerich, assignee. Radiolabeled cannabinoid receptor 2 ligand. WO patent WO 2020/002314 A1. 2020 [2019 Jun 25].
   Google Scholar
• Haider A, Gobbi L, Kretz J, et al. Identification and preclinical development of a 2,5,6-trisubstituted fluorinated pyridine derivative as a radioligand for the positron emission tomography imaging of cannabinoid type 2 receptors. J Med Chem. [2020 Sep 24];63(18):10287–10306. doi: 10.1021/acs.jmedchem.0c00778.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet] NCT05880563, investigation of cannabinoid 2-receptor expression in the brain and spine of ALS-patients compared to healthy controls with PET (18F-RoSMALS). Bethesda (MD): National Library of Medicine, US; cited 2000 Feb 29. Available from: https://clinicaltrials.gov/study/NCT05880563
   Google Scholar
• Frei B, Gobbi L, Grether UWE, et al., inventors; Hoffmann La Roche, assignee. Pyridine derivatives. WO patent WO 2018/234284 A1. 2018 [2018 Jun 19].
   Google Scholar
• Porter RF, Szczesniak A-M, Toguri JT, et al. Selective cannabinoid 2 receptor agonists as potential therapeutic drugs for the treatment of endotoxin-induced uveitis. Molecules. 2019;24(18):3338. doi: 10.3390/molecules24183338
   PubMed Web of Science ®Google Scholar
• Ouali Alami N, Schurr C, Olde Heuvel F, et al. NF-kappaB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS. Embo J. 2018 Aug 15;37(16). doi: 10.15252/embj.201798697
   PubMed Web of Science ®Google Scholar
• Gobbi L, Grether UWE, Guba W, et al., inventors; Hoffmann La Roche, assignee. Novel [1,2,31triazolo4,5-d]pyrimidine Derivatives. WO patent WO 2018/015088 A1. 2018 [2017 Jun 20].
   Google Scholar
• Gobbi L, Grether UWE, Guba W, et al., inventors; Hoffmann La Roche, assignee. Novel[1,2,3]triazolo4,5-d]pyrimidine derivatives. WO patent WO 2017/220544 A1. 2017 [2017 Jun 20].
   Google Scholar
• Gobbi L, Grether UWE, Guba W, et al., inventors; Hoffmann La Roche, assignee. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor. WO patent WO 2017/220517 A1. 2017 [2017 Jun 20].
   Google Scholar
• Gobbi L, Grether UWE, Guba W, et al., inventors; Hoffmann La Roche, assignee. Novel [1,2,3]triazolo[4,5-d]pyrimidine Derivatives. WO patent WO 2017/220516 A1. 2017 [2017 Jun 20].
   Google Scholar
• Westphal MV, Sarott RC, Zirwes EA, et al. Highly Selective, Amine-Derived Cannabinoid Receptor 2 Probes. Chem A Eur J. [2020 Jan 27];26(6):1380–1387. doi: 10.1002/chem.201904584
   PubMed Web of Science ®Google Scholar
• Soethoudt M, Stolze SC, Westphal MV, et al. Selective Photoaffinity Probe That Enables Assessment of Cannabinoid CB(2) Receptor Expression and Ligand Engagement in Human Cells. J Am Chem Soc. 2018 May 16;140(19):6067–6075. doi: 10.1021/jacs.7b11281
   PubMed Web of Science ®Google Scholar
• Gavelle O, Grether UWE, Nettekoven M, et al., inventors; Hoffmann La Roche, assignee. Phenyl derivatives as cannabinoid receptor 2 agonists. WO patent WO 2017/097732 A1. 2017 [2016 Dec 6].
   Google Scholar
• Caterina B, Uwe G, Paul H, et al., inventors; Hoffmann La Roche, assignee. Pyridine-2-amides capable of being used as CB2 agonist. CN patent CN 106349156 A. 2017 [2012 Jun 7].
   Google Scholar
• Grether UWE, Nettekoven M, Rogers-Evans M, et al., inventors; Hoffmann La Roche, assignee. Triazolo[4,5-D]pyrimidines as agonists of the cannabinoid receptor 2. WO patent WO 2016/071375 A1. 2016 [2015 Nov 4].
   Google Scholar
• Stinchcomb Audra L, Golinski Miroslaw J, Hammell Dana C, et al., inventors; Zynerba Pharmaceuticals Inc, assignee. Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same. US patent US 2022/0194916 A1. 2022 [2021 Nov 24].
   Google Scholar
• Chen J, Xie XIN, Qian H, et al., inventors; UNIV Zhejiang, Shanghai Inst Materia Medica Cas, assignee. Pyridazine derivative and preparation method and application thereof. CN patent CN 106187910 A. 2016 [2016 Jul 7].
   Google Scholar
• Qian HY, Wang ZL, Xie XY, et al. Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies. Eur J Med Chem. 2017 Sep 8;137:598–611. doi: 10.1016/j.ejmech.2017.05.060
   PubMed Web of Science ®Google Scholar
• Yu L, Xie XIN, Li J, et al., inventors; Univ East China Normal, Shanghai Inst Materia Medica Cas, assignee. Azaindole derivative and preparation method and application thereof. CN patent CN 111518095 A. 2020 [2019 Feb 2].
   Google Scholar
• Makriyannis A, Liu Q, inventors; Univ Connecticut, Makriyannis Alexandros, Liu Qian, assignee. Heteroindanes: a new class of potent cannabimimetic ligands. WO patent WO 2003/035005 A3. 2003 [2002 Oct 28].
   Google Scholar
• Yu L, Xie XIN, Shi Y, et al., inventors; Univ East China Normal, Shanghai Inst Materia Medica Cas, assignee. 1H-indole-2-carboxamide derivative and preparation method and applications thereof. CN patent CN 108794379 A. 2018 [2017 Apr 26].
   Google Scholar
• Shi Y, Duan YH, Ji YY, et al. Amidoalkylindoles as Potent and Selective Cannabinoid Type 2 Receptor agonists with in vivo efficacy in a mouse model of multiple sclerosis. J Med Chem. 2017 Aug 24;60(16):7067–7083. doi: 10.1021/acs.jmedchem.7b00724
   PubMed Web of Science ®Google Scholar
• Shen J, He Y, Wu C, et al., inventors; Shanghai Inst Materia Medica Cas, Topharman Shanghai Co Ltd, Lian V Nantong Co Ltd, assignee. Resorcinol compounds, preparation method therefor and use thereof in nervous system diseases. WO patent WO 2022/105810 A1. 2022 [2021 Nov 17].
   Google Scholar
• Ge H, Xie XIN, Li J, et al., inventors; Huzhou Teachers College, Shanghai Inst Materia Medica Cas, assignee. Benzene methylene thiazolidinedione derivative as well as preparation method and application thereof. CN patent CN 114890963 A. 2022 [2022 Apr 18].
   Google Scholar
• Chen J, Xie XIN, Qian H, et al., inventors; Univ Zhejiang, Shanghai Inst Materia Medica Cas, assignee. Quinazoline dione derivatives and preparation method and application thereof. CN patent CN 106146414 A. 2016 [2016 Jul 7].
   Google Scholar
• Chen J, Xie XIN, Qian H, et al., inventors; Univ Zhejiang, Shanghai Inst Materia Medica Cas, assignee. Heteroarylpyrimindinedione derivative and use thereof. CN patent CN 106167497 A. 2016 [2016 Jul 7].
   Google Scholar
• Qian HY, Wang ZL, Pan YL, et al. Development of Quinazoline/Pyrimidine-2,4(1H,3H)-diones as agonists of cannabinoid receptor type 2. ACS Med Chem Lett. 2017 Jun 8;8(6):678–681. doi: 10.1021/acsmedchemlett.7b00007
   PubMed Web of Science ®Google Scholar
• Qian HY, Wang ZL, Chen LL, et al. Design, Synthesis, and SAR studies of heteroarylpyrimidines and heteroaryltriazines as CB(2) R ligands. ChemMedChem. 2018 Nov 20;13(22):2455–2463. doi: 10.1002/cmdc.201800541
   PubMed Web of Science ®Google Scholar
• Checketts D, Craig K, inventors; GW RES LTD, assignee. Use of cannabidiol in the treatment of seizures associated with chrna4 mutation. WO patent WO 2022/017949 A1. 2022 [2021 Jul 15].
   Google Scholar
• Burstein SH, Karst M, Schneider U, et al. Ajulemic acid: a novel cannabinoid produces analgesia without a “high”. Life Sci. 2004 2004 Aug 6;75(12):1513–1522. doi: 10.1016/j.lfs.2004.04.010
   PubMed Web of Science ®Google Scholar
• Zurier Robert B, Selvi E, inventors; Corbus Pharmaceuticals Inc, assignee. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids. US patent US 2018/0116999 A1. 2018 [2017 Jun 9].
   Google Scholar
• White B, inventor; Corbus Pharmaceuticals Inc, assignee. Compositions and methods for attenuating side effects of immune checkpoint inhibitor therapy. WO patent WO 2021/021543 A1. 2021 [2020 Jul 23].
   Google Scholar
• Leigh C, Zhang Y, Moshos K, et al. inventors; Corbus Pharmaceuticals Inc, assignee. Cannabinoids and uses thereof. WO patent WO 2019/232413 A1. 2019 [2019 May 31].
   Google Scholar
• Deng H, Evron T, Jin Z, et al., inventors; Corbus Pharmaceuticals Inc, assignee. Cannabinoids and uses thereof. WO patent WO 2021/067834 A1. 2021 [2020 Oct 2].
   Google Scholar
• Deng H, Evron T, Leigh C, et al., inventors; Corbus Pharmaceuticals Inc, assignee. Cannabinoids and uses thereof. WO patent WO 2021/087127 A1. 2021 [2020 Oct 29].
   Google Scholar
• Deng H, Leigh C, Jin Z, inventors; Corbus Pharmaceuticals Inc, assignee. cannabinoids and uses thereof. WO patent WO 2021/113656 A1. 2021 [2020 Dec 4].
   Google Scholar
• Deng H, Discordia R, Feng X, et al., inventors; Corbus Pharmaceuticals Inc, assignee. Cannabinoids and uses thereof. WO patent WO 2021/113669 A1. 2021 [2020 Dec 4].
   Google Scholar
• Li YAO, Wang W, Zhang G, et al., inventors; Sichuan haisco pharmaceutical co ltd, assignee. tricyclic pyrazole derivative and preparation thereof. WO patent WO 2021/047583 A1. 2021 [2020 Sep 10].
   Google Scholar
• Li YAO, Chen LEI, Wang W, et al., inventors; Sichuan Haisco Pharmaceutical Co Ltd, assignee. Hexahydrobenzopyrazole derivative and preparation therefof. WO patent WO 2021/047581 A1. 2021 [2020 Sep 10].
   Google Scholar
• Li YAO, Wang W, Zhang C, et al. inventors; Haisco Pharmaceutical Group Inc, assignee. Substituted pyrazolocyclohexane derivative crystal form. CN patent CN 114933592 A. 2022 [2021 Dec 13].
   Google Scholar
• Li YAO, Wang W, Tang P inventors; Heixidae Medicine Group Stock Ltd Company, assignee. Hexahydrobenzopyrazole cannabinoid receptor 2 agonist and application thereof. CN patent CN 114478488 A. 2022 [2021 Nov 10].
   Google Scholar
• Li YAO, Chen LEI, Zhang G, et al., inventors; Sichuan Haisco Pharmaceutical Co Ltd, assignee. Polycyclic derivatives and preparation thereof. CN patent CN 112480121 A. 2021 2020/09/10.
   Google Scholar
• Zhou L inventor; Univ Chengdu Technology, assignee. Novel cannabinoid receptor 2(CB2) agonist. CN patent CN 106317059 A. 2017 [2016 Aug 19].
   Google Scholar
• Zhou L, inventor; Univ Chengdu Technology, assignee. Novel cannabinoid receptor 2 agonist. CN patent CN 106317043 A. 2017 [2016 Aug 19].
   Google Scholar
• Moustafa Mahmoud Mohamed A, inventor; London Pharmaceuticals and Res Corporation, assignee. Rigid cannabidiol analogues as potent modulators of cannabinoid receptors and uses thereof. WO patent WO 2021/243468 A1. 2021 [2021 Jun 4].
   Google Scholar
• Clarke C, Moustafa Mahmoud Mohamed A, Mayhoub Abdelrahman S, inventors; London Pharmaceuticals and Res Corporation, assignee. Psilocybin and psilocin conjugates for treatment of mental illnesses. WO patent WO 2022/236407 A1. 2022 [2022 May 10].
   Google Scholar
• Moustafa Mahmoud Mohamed A, inventor; London Pharmaceuticals And Res Corporation, assignee. Chewing gum containing synergistic medicinal compounds. WO patent WO 2021/092684 A1. 2021 [2020 Nov 12].
   Google Scholar
• Thakur G, Garai S, inventors; Univ Northeastern, assignee. N-substituted indoles and use as allosteric modulators of cannabinoid receptors. WO patent WO 2020/006152 A1. 2020 [2019 Jun 26].
   Google Scholar
• Cairns EA, Szczesniak AM, Straiker AJ, et al. The Effects of the CB1-positive allosteric modulator GAT229 on intraocular pressure in ocular normotensive and hypertensive mice. J Ocul Pharmacol Th. 2017 Oct;33(8):582–590. doi: 10.1089/jop.2017.0037
   PubMed Web of Science ®Google Scholar
• Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev. 2000 Jan;20(1):58–101. doi: 10.1002/(SICI)1098-1128(200001)20:1<58:AID-MED3>3.0.CO;2-X
   PubMed Web of Science ®Google Scholar
• Makriyannis A, Nikas Spyridon P, Thakur Ganeshsingh A, et al. inventors; Univ Northeastern, assignee. Cannabinergic compounds and uses thereof. US patent US 2021/0101878 A1. 2021 [2020 Dec 11].
   Google Scholar
• Kulkarni S, Nikas SP, Sharma R, et al. Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues. J Med Chem. 2016 Jul 28;59(14):6903–6919. doi: 10.1021/acs.jmedchem.6b00717
   PubMed Web of Science ®Google Scholar
• Zhang H, Lu W, Liu M, et al., inventors; Univ East China Normal, Shanghai Bangyao Biotechnology Co Ltd, assignee. Nitrogen-containing five-membered heteroaromatic compound and preparation method and application thereof. CN patent CN 109516955 A. 2019 [2017 Sep 20].
   Google Scholar
• Lu W, Zhang H, Chen SI, et al., inventors; UNIV EAST CHINA NORMAL, BIORAY LABORATORIES INC, assignee. Compound for treating hepatic fibrosis and scleroderma and application of compound. CN patent CN 110604735 A. 2019 [2019 Sep 18].
   Google Scholar
• Jiang BE, Jiang XW, Zhang QS, et al. From a designer drug to the discovery of selective cannabinoid type 2 receptor agonists with favorable pharmacokinetic profiles for the treatment of systemic sclerosis. J Med Chem. 2021 Jan 14;64(1):385–403. doi: 10.1021/acs.jmedchem.0c01023
   PubMed Web of Science ®Google Scholar
• Elzein E, Liu J, inventors; Teon Therapeutics Inc, assignee. Cannabinoid receptor type 2 (cb2) modulators and uses thereof. WO patent WO 2021/226206 A20. 2021 [2021 May 5].
   Google Scholar
• Xiong X, Chen S, Shen J, et al. Cannabis suppresses antitumor immunity by inhibiting JAK/STAT signaling in T cells through CNR2. Signal Transduct Target Ther. 2022 [2022 Apr 6];7(1):99. doi: 10.1038/s41392-022-00918-y
   PubMed Web of Science ®Google Scholar
• Lucchesi V, Hurst DP, Shore DM, et al. CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-naphthyridin-2(1H)-one-3-carboxamides. J Med Chem. 2014 [2014 Nov 13];57(21):8777–8791. doi: 10.1021/jm500807e
   PubMed Web of Science ®Google Scholar
• Elzein E, Liu J, inventors; Teon Therapeutics Inc, assignee. 4-Hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer. WO patent WO 2023/081730 A1. 2023 [2022 Nov 2].
   Google Scholar
• Das A, Roy J, inventors; Univ Illinois, Dasaditi, Roy Jahnabi, assignee. Docosahexaenoic acid endocannabinoid epoxide derivative compositions. WO patent WO 2019/060507 A1. 2019 [2018 Sep 20].
   Google Scholar
• Das A, Watson Josephine E, inventors; Univ Illinois, Das Aditi, Watson Josephine E, assignee. Derivatives of epa endocannabinoid epoxides as anti-inflammatory, anti-cancerous, anti-angiogenc and antiplatelet aggregation compounds. WO patent WO 2019/060508 A1. 2019 [2018 Sep 20].
   Google Scholar
• Yang P, Myint K-Z, Tong Q, et al. Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors. J Med Chem. 2012 [2012 Nov 26];55(22):9973–9987. doi: 10.1021/jm301212u
   PubMed Web of Science ®Google Scholar
• Ouyang Q, Tong Q, Feng R, et al. Trisubstituted sulfonamides: a new chemotype for development of potent and selective CB(2) receptor inverse agonists. ACS Med Chem Lett. [2013 Apr 11];4(4):387–392. doi: 10.1021/ml3004236
   PubMed Web of Science ®Google Scholar
• Xie X-Q, Almehizia A, Yang P, inventors; Univ of Pittsburgh - of The Commonwealth System of Higher Education, assignee. Novel cannabinoid receptor CB2 ligand 4-(aminomethyl)-n,n-dialkylanilines. WO patent WO 2016/205707 A1. 2016 [2016 Jun 17].
   Google Scholar
• Xie X-Q, Yang P, Feng R, inventors; Univ Of Pittsburgh - of The Commonwealth System of Higher Education, assignee. Novel cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases. US patent US 2017/0001949 A1. 2017 [2016 May 31].
   Google Scholar
• Mechoulam R, Breuer A, Pereira Kapczinski F, et al., inventors; YIssum Res Dev Co, Univ Fed Do Rio Grande Do Sul – Ufrgs, Univ De São Paulo - Usp, assignee. Fluorinated cbd compounds, compositions and uses thereof. WO patent WO 2017/008136 A2. 2017 [2016 Jul 15].
   Google Scholar
• Breuer A, Haj CG, Fogaca MV, et al. Fluorinated cannabidiol derivatives: enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects. PLOS ONE. 2016;11(7):e0158779. doi: 10.1371/journal.pone.0158779
   PubMed Web of Science ®Google Scholar
• Silva NR, Gomes FV, Fonseca MD, et al. Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative. Prog Neuropsychopharmacol Biol Psychiatry. [2017 Oct 3];79(Pt B):369–377. doi: 10.1016/j.pnpbp.2017.07.012
   PubMedGoogle Scholar
• Aizikovich A, inventor; AL&AM Pharmachem Ltd, assignee. Cannabinolic acid derivatives and uses thereof. WO patent WO 2019/234728 A1. 2019 [2019 May 19.
   Google Scholar
• Morales P, Jagerovic N. Antitumor cannabinoid chemotypes: structural insights. Front Pharmacol. 2019;10:621. doi: 10.3389/fphar.2019.00621
   PubMed Web of Science ®Google Scholar
• Barr Philip J, Marlowe Charles K, Sun J, et al., inventors; Baymedica Inc, assignee. Cannabinoid analogs and methods for their preparation. WO patent WO 2020/092823 A1. 2020 [2019 Oct 31.
   Google Scholar
• Udoh M, Santiago M, Devenish S, et al. Cannabichromene is a cannabinoid CB(2) receptor agonist. Br J Pharmacol. 2019 Dec;176(23):4537–4547. doi: 10.1111/bph.14815
   PubMed Web of Science ®Google Scholar
• Zhang J, Xu X, Wei Y, et al., inventors; Chengdu Baiyu Pharmaceutical Co Ltd, assignee. Tetrahydrocannabinol derivative, and preparation method therefor and medical use thereof. WO patent WO 2021/139740 A1. 2021 [2021 Jan 7.
   Google Scholar
• Sun YI, Chu H, Su G, et al., inventors; Chengdu Baiyu Pharmaceutical Co Ltd, assignee. Pharmaceutical composition containing ginkgolide and cannabinoid compounds and use thereof in medicine. WO patent WO 2021/175311 A1. 2021 [2021 Mar 5].
   Google Scholar
• Xiang Y, Zeng S, Ma Y, et al., inventors; Chengdu Easton Biopharmaceuticals CO LTD, assignee. 2H-benzo [b] [1, 4] oxazine-3 (4H)-one derivatives. CN patent CN 115677611 A. 2023 [2022 Jun 6].
   Google Scholar
• Liang X, Zhou HAN, Peng X, et al. inventors; Dalian Inst Chem & Physics Cas, assignee. Application of compound as or in preparation of cannabinoid receptor agonist or antagonists. CN patent CN 111789860 A. 2020 [2019 Apr 9].
   Google Scholar
• Codd EE, Mabus JR, Murray BS, et al. Dynamic mass redistribution as a means to measure and differentiate signaling via opioid and cannabinoid receptors. Assay Drug Dev Technol. 2011 Aug;9(4):362–372. doi: 10.1089/adt.2010.0347
   PubMed Web of Science ®Google Scholar
• Moldovan R-P, Teodoro R, Toussaint M, et al., inventors; HELMHOLTZ ZENTRUM DRESDEN, assignee. Deuterated and tritiated n-(4,5-dimethylthiazolo-2(3h)-yliden)-2,2,3,3-tetramethylcyclopropane-1-carboxamide derivatives and their use. WO patent WO 2022/008006 A1. 2022 [2021 Jul 9].
   Google Scholar
• Caille F, Cacheux F, Peyronneau MA, et al. From structure-activity relationships on thiazole derivatives to the in vivo evaluation of a new radiotracer for cannabinoid subtype 2 PET imaging. Mol Pharm. [2017 Nov 6];14(11):4064–4078. doi: 10.1021/acs.molpharmaceut.7b00746
   PubMedGoogle Scholar
• Moldovan RP, Teodoro R, Gao Y, et al. Development of a high-affinity PET radioligand for imaging cannabinoid subtype 2 receptor. J Med Chem. 2016 Sep 8;59(17):7840–7855. doi: 10.1021/acs.jmedchem.6b00554
   PubMed Web of Science ®Google Scholar
• Prosper Juan A P, Martín Nuria E C, Pérez Martín C, et al., inventors; Consejo Superior De Investig Científicas (CSIC). Univ Rey Juan Carlos, Hospital Univ Fundación Alcorcón, assignee. Novel family of carbonyl derivatives of 1-indazolyl with cannabinoid and/or cholinergic and/or beta-amyloid-peptide-regulating properties. WO patent WO 2017/103319 A1. 2017 [2016 Dec 16].
   Google Scholar
• Prosper Juan AP, Martin Nuria EC, Gonzales Naranjo P, et al., inventors; Univ Rey Juan Carlos, Paez Prosper Juan Antonio, Campillo Martin Nuria Eugenia, Gonzales Naranjo Pedro, Perez Martin Concepcion, Aran Redo Vicente Jesus, Martin Fontelles Ma Isabel, Giron Moreno Rocio, Sanchez Robles Eva Ma, assignee. 3-indazolyl ether family with cannabinoid and/or cholinergic properties. WO patent WO 2011/039388 A2. 2011 [2010 Sep 30.
   Google Scholar
• Ramirez BG, Blazquez C, Gomez Del Pulgar T, et al. Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci. 2005 Feb 23;25(8):1904–1913. doi: 10.1523/JNEUROSCI.4540-04.2005
   PubMed Web of Science ®Google Scholar
• Martin-Moreno AM, Brera B, Spuch C, et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation. [2012 Jan 16];9(1):8. doi: 10.1186/1742-2094-9-8
   PubMedGoogle Scholar
• Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol. 2006 Feb;9(1):101–124. doi: 10.1017/S1461145705005833
   PubMed Web of Science ®Google Scholar
• Huang WH, Sheng R, Hu YZ. Progress in the development of nonpeptidomimetic BACE 1 inhibitors for Alzheimer’s disease. Curr Med Chem. 2009;16(14):1806–1820. doi: 10.2174/092986709788186174
   PubMed Web of Science ®Google Scholar
• Nunez-Borque E, Gonzalez-Naranjo P, Bartolome F, et al. Targeting cannabinoid receptor activation and BACE-1 activity counteracts TgAPP mice memory impairment and alzheimer’s disease lymphoblast alterations. Mol Neurobiol. 2020 Apr;57(4):1938–1951. doi: 10.1007/s12035-019-01813-4
   PubMed Web of Science ®Google Scholar
• Meegalla Sanath K, Player Mark R, inventors; Janssen Pharmaceutica Nv, assignee. Hexahydro-5,8-epoxycyclohepta[c]pyrazole derivatives useful as modulators of the cb1 and/or cb2 receptors. WO patent WO 2021/069671 A1. 2021 [2020 Oct 9].
   Google Scholar
• Scheiner M, Dolles D, Decker M, inventors; Univ Wuerzburg J Maximilians, assignee. Cannabinoid receptor subtype 2 stimulator inhibiting acetylcholinesterase and butyrylcholinesterase. WO patent WO 2021/018699 A1. 2021 [2020 Jul 22].
   Google Scholar
• Scheiner M, Dolles D, Gunesch S, et al. Dual-acting cholinesterase-human cannabinoid receptor 2 ligands show pronounced neuroprotection in vitro and overadditive and disease-modifying neuroprotective effects in vivo. J Med Chem. [2019 Oct 24];62(20):9078–9102. doi: 10.1021/acs.jmedchem.9b00623
   PubMed Web of Science ®Google Scholar
• Dolles D, Hoffmann M, Gunesch S, et al. Structure-activity relationships and computational investigations into the development of potent and balanced dual-acting butyrylcholinesterase inhibitors and human cannabinoid receptor 2 ligands with pro-cognitive in vivo profiles. J Med Chem. 2018 Feb 22;61(4):1646–1663. doi: 10.1021/acs.jmedchem.7b01760
   PubMed Web of Science ®Google Scholar
• Laufer R, Summa V, inventors; Merit therapeutics INC, assignee. Deuterated cannabinoid compounds. WO patent WO 2022/159504 A1. 2022 [2022 Jan 19].
   Google Scholar
• Heimann AS, Gomes I, Dale CS, et al. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci USA. 2007 Dec 18;104(51):20588–20593. doi: 10.1073/pnas.0706980105
   PubMed Web of Science ®Google Scholar
• Heimann Andrea S, Dale Camila S, Devi Lakshmi A, inventors; Soc beneficente de senhoras hospital sirio libanes, assignee. Pharmaceutical composition for treating medical conditions and a method for treating alimentary disorders and related diseases. US patent US 9452196 B2. 2016 [2015 May 4].
   Google Scholar
• Alves Xapeli S, Oliveira Malva Joao J, De Mollo Reis Ricardo A, inventors; Univ de coimbra, williams gareth, alves xapeli sara, oliveira malva joao jose, de mollo reis ricardo augusto, assignee. Oligodendrocyte differentiation. WO patent WO 2013/021196 A2. 2013 [2012 Aug 8].
   Google Scholar
• Remer Ricardo A, Heimann Andrea S, inventors; Proteimax biotecnologia ltda, remer consultores assessoria empresarial Ltd, assignee. Use of a compound, pharmaceutical composition, and therapeutic method for the treatment or prevention of convulsions. WO patent WO 2018/068119 A1. 2018 [2017 Oct 11].
   Google Scholar
• Remer Ricardo A, Heimann Andrea S, inventors; Proteimax biotecnologia ltda, remer consultores assessoria empresarial Ltd, assignee. Use of a compound, synthetic intermediate, pharmaceutical composition, and neuromodulatory therapeutic method. WO patent WO 2018/068120 A1. 2018 [2017 Oct 11].
   Google Scholar
• Remer Ricardo A, Heimann Andrea S, inventors; Remer consultores assessoria empresarial ltda, proteimax biotecnologia Ltd, assignee. Compound, synthetic intermediate, use, pharmaceutical composition, and neuromodulatory therapeutic method. EP patent EP 3626727 A1. 2020 [2018 May 14].
   Google Scholar
• Heimann AS, Giardini AC, Sant’anna MB, et al. NFKF is a synthetic fragment derived from rat hemopressin that protects mice from neurodegeneration. Neurosci Lett. 2020 Mar 16;721:134765. doi: 10.1016/j.neulet.2020.134765
   PubMed Web of Science ®Google Scholar
• Bomar MG, Galande AK. Modulation of the cannabinoid receptors by hemopressin peptides. Life Sci. 2013 Mar 19;92(8–9):520–524. doi: 10.1016/j.lfs.2012.07.028
   PubMed Web of Science ®Google Scholar
• Remer Ricardo A, Heimann Andrea S, inventors; Proteimax Biotecnologia Ltd, Remer Consultores Assessoria Empresarial Ltda, assignee. Use of compound, pharmaceutical composition for the treatment of immune or metabolic disorders, pharmaceutical composition for the treatment of illnesses caused by or associated with viruses. WO patent WO 2022/155716 A1. 2022 [2022 Jan 7].
   Google Scholar
• Offen D, Yom-Tov N, inventors; UNIV RAMOT, assignee. Cannabinoid-lipid conjugates, methods for producing the same and uses thereof. WO patent WO 2023/047399. 2023 [2022 Sep 22]:p. A1.
   Google Scholar
• Zielinska A, Cano A, Andreani T, et al. Lipid-Drug Conjugates and Nanoparticles for the Cutaneous Delivery of Cannabidiol. Int J Mol Sci. [2022 May 31];23(11):6165. doi: 10.3390/ijms23116165
   PubMed Web of Science ®Google Scholar
• Amato G, Rangan M, Runyon S, inventors; RTI INT INC, assignee. Indazole derivatives as cannabinoid receptor partial agonists. WO patent WO 2021/155227 A1. 2021 [2021 Jan 29].
   Google Scholar
• Fortin Samuel C, inventor; SCF Pharma INC, assignee. Cannabidiolic acid monoglycerides, derivatives, and uses thereof. WO patent WO 2020/198874 A1. 2020 [2020 Apr 3].
   Google Scholar
• Citti C, Pacchetti B, Vandelli MA, et al. Analysis of cannabinoids in commercial hemp seed oil and decarboxylation kinetics studies of cannabidiolic acid (CBDA). J Pharm Biomed Anal. 2018 Feb 5;149:532–540. doi: 10.1016/j.jpba.2017.11.044
   PubMed Web of Science ®Google Scholar
• Gotz MR, Collado JA, Fernandez-Ruiz J, et al. Structure-effect relationships of novel semi-synthetic cannabinoid derivatives. Front Pharmacol. 2019;10:1284. doi: 10.3389/fphar.2019.01284
   PubMed Web of Science ®Google Scholar
• Fortin Samuel C, inventor; Scf Pharma Inc, assignee. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof. WO patent WO 2019/210424 A1. 2019 [2019 May 3].
   Google Scholar
• Fortin Samuel C, inventor; SCF PHARMA INC, assignee. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof. WO patent WO 2021/012046 A1. 2021 [2020 Jul 21].
   Google Scholar
• Cheng J, Liu Z, Zhang Z, et al. inventors; UNIV SHANGHAI TECH, assignee. Cannabinoid compound as well as preparation method, composition and application thereof. CN patent CN 112047973 A. 2020 [2020 Jun 8].
   Google Scholar
• Duan W, Sun Y, Wu M, et al. Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis. Eur J Med Chem. 2021 Dec 15;226:113878. doi: 10.1016/j.ejmech.2021.113878
   PubMed Web of Science ®Google Scholar
• Eshel N, Green M, Jahangir A, et al. inventors; UNiv Leland Stanford Junior, Eshel Neir, assignee. CB2 Receptor Agonists. WO patent WO 2022/132803 A1. 2022 [2021 Dec 14].
   Google Scholar
• Xu X, Cai PE, Cao S, inventors; SUn Yat Sen Memorial Hospital Sun Yat Sen Univ, assignee. Novel intracellular response nanoparticle loaded with target gene siRNA and preparation method of novel intracellular response nanoparticle. CN patent CN 113209043 A. 2021 [2020 Jan 19].
   Google Scholar
• Diaz P, Diaz F, Petrov Ravil R, inventors; The Univ of Montana, assignee. Novel tricyclic modulators of cannabinoid receptors. US patent US 2017/0096426 A1. 2017 [2016 Oct 7].
   Google Scholar
• Shao H, Chen X, Wang Z, et al. Synthesis and fluorescence properties of carbazole and fluorene-based compounds. J Lumin. 2007 [2007 Dec 1];127(2):349–354. doi: 10.1016/j.jlumin.2007.01.013
   Web of Science ®Google Scholar
• Silver David L, Ahmed M, Sing Yeung F M. inventors; Travecta Therapeutics Inc, assignee. Anandamide compounds. WO patent WO 2020/146771 A1. 2020 [2020 Jan 10].
   Google Scholar
• Ahmed M, Mak Sing Yeung F, Puthukanoori Ravi K, et al., inventors; Travecta Therapeutics Pte LTD, assignee. Process of preparing arachidonoylethanolamine analogues. WO patent WO 2021/099554 A1. 2021 [2020 Nov 20].
   Google Scholar
• Tömböly C, Dvorácskó S, Mollica A, et al., inventors; Univ Degli Studi G D Annunzio Chieti Pescara, Biological Res Centre of The Hungarian Academy Of Sciences, assignee. Indazole derivatives as modulators of the cannabinoid system. EP patent EP 3564214 A1. 2019 [2018 May 4].
   Google Scholar
• Buchler Ingrid P, Hayes Michael J, Hedge Shridhar G, et al., inventors; Pfizer, Buchler Ingrid Price, Hayes Michael Joseph, Hedge Shridhar Gajanan, Hockerman Susan Landis, Jones Darin Eugene, Kortum Steven Wade, Rico Joseph Gerace, Tenbrink Ruth Elizabeth, Wu Kun Ken, assignee. INDAZOLE DERIVATIVES. WO patent WO 2009/106982 A1. 2009 [2009 Feb 26].
   Google Scholar
• Uchiyama N, Matsuda S, Kawamura M, et al. Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products. Forensic Toxicol. 2013 Jul;31(2):223–240.
   Web of Science ®Google Scholar
• Franz A, Cobo A, inventors; UNIV CALIFORNIA, assignee. Silyl-lipid cannabinoids with enhanced biological activity. WO patent WO 2023/146914 A1. 2023 [2023 Jan 25].
   Google Scholar
• Mills JS, Showell GA. Exploitation of silicon medicinal chemistry in drug discovery. Expert Opin Investig Drugs. 2004 Sep;13(9):1149–1157. doi: 10.1517/13543784.13.9.1149
   PubMed Web of Science ®Google Scholar
• Mu L, Bieri D, Slavik R, et al. Radiolabeling and in vitro/in vivo evaluation of N-(1-adamantyl)-8-methoxy-4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxamide as a PET probe for imaging cannabinoid type 2 receptor. J Neurochem. 2013 Sep;126(5):616–624. doi: 10.1111/jnc.12354
   PubMed Web of Science ®Google Scholar
• Ametamey Simon M, Slavik R, Mu L, inventors; Eth Zuerich, Univ Zuerich, assignee. 4-OXO-1,4-Dihydroquinoline-3-carboxamide As Selective Ligand For Cannabinoid Receptor 2 For Diagnosis And Therapy. WO patent WO 2016/005419 A1. 2016 [2015 Jul 8.
   Google Scholar
• Slavik R, Herde AM, Bieri D, et al. Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor. Eur J Med Chem. 2015 Mar 6;92:554–564. doi: 10.1016/j.ejmech.2015.01.028
   PubMed Web of Science ®Google Scholar
• Meletta R, Slavik R, Mu L, et al. Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evaluation of the novel radiotracer [(11)C]RS-016 targeting CB2 in atherosclerosis. Nucl Med Biol. 2017 Apr;47:31–43. doi: 10.1016/j.nucmedbio.2017.01.001
   PubMed Web of Science ®Google Scholar
• Slavik R, Muller Herde A, Haider A, et al. Discovery of a fluorinated 4-oxo-quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2. J Neurochem. 2016 Sep;138(6):874–886. doi: 10.1111/jnc.13716
   PubMed Web of Science ®Google Scholar
• Mohamed Ali Mohamed Ali I, Paris Jason R, Walker Larry A, et al., inventors; UNIV MISSISSIPPI, assignee. Orally bioavailable, brain-penetrant compound with selectivity for the cannabinoid type 2 receptor with potential use towards visceral pain management and neurodegenerative disorders. US patent US 2023/0303581 A1. 2023 [2023 Mar 28.
   Google Scholar
• Ospanov M, Sulochana SP, Paris JJ, et al. Identification of an Orally Bioavailable, Brain-Penetrant Compound with Selectivity for the Cannabinoid Type 2 Receptor. Molecules. 2022 Jan 14;27(2):509. doi: 10.3390/molecules27020509
   PubMed Web of Science ®Google Scholar
• Mingle D, Ospanov M, Radwan MO, et al. First in class (S,E)-11-[2-(Arylmethylene)Hydrazono]-PBD analogs as selective CB2 modulators targeting neurodegenerative disorders. Med Chem Res. 2021 Jan;30(1):98–108. doi: 10.1007/s00044-020-02640-2
   PubMed Web of Science ®Google Scholar
• Li H, Liu XU, Meng S, et al., inventors; Yunnan Han Union Pharmaceutical Co Ltd, assignee. Cannabinoid glycoside and preparation method thereof. CN patent CN 114573648 A. 2022 [2020 Nov 30.
   Google Scholar
• Zhang KE, Tan XIN, Chang T, et al., inventors; HANYI Biological Tech Beijing CO LTD, assignee. Application of cannabinoid compounds in the treatment of neurodermatitis. CN patent CN 109200046 A. 2019 [2017 Jul 4].
   Google Scholar
• Maccarrone M, Grether U. “Is CB₂R a hidden treasure trove for treating inflammatory diseases?” Open Access Government. 2022 Oct; [cited 2023 Dec]. Available from p. 28–29. Available from: https://www.openaccessgovernment.org/article/cb%e2%82%82r-treating-inflammatory-diseases-endocannabinoid-system/145866/
   Google Scholar
• Li X, Shen L, Hua T, et al. Structural and functional insights into cannabinoid receptors. Trends Pharmacol Sci. 2020 Sep;41(9):665–677. doi: 10.1016/j.tips.2020.06.010
   PubMed Web of Science ®Google Scholar
• Atz K, Guba W, Grether U, et al. Machine learning and computational chemistry for the endocannabinoid system. Methods Mol Biol. 2023;2576:477–493.
   PubMedGoogle Scholar
• Nazare M, Grether U. Visualizing the anti-inflammatory cannabinoid Type-2 receptor: Open Access Government. 2023 Apr [cited 2023 Dec]. p. 30–31. Available from: https://www.openaccessgovernment.org/article/visualizing-the-anti-inflammatory-cannabinoid-type-2-receptor/155448/
   Google Scholar
• Guberman M, Kosar M, Omran A, et al. Reverse-design toward optimized labeled chemical probes – examples from the endocannabinoid system. Chimia (Aarau). 2022 May 25;76(5):425. doi: 10.2533/chimia.2022.425
   PubMed Web of Science ®Google Scholar
• Gazzi T, Brennecke B, Atz K, et al. Detection of cannabinoid receptor type 2 in native cells and zebrafish with a highly potent, cell-permeable fluorescent probe. Chem Sci. 2022 May 18;13(19):5539–5545. doi: 10.1039/D1SC06659E
   PubMed Web of Science ®Google Scholar
• Sarott RC, Westphal MV, Pfaff P, et al. Development of high-specificity fluorescent probes to enable cannabinoid type 2 receptor studies in living cells. J Am Chem Soc. 2020 Oct 7;142(40):16953–16964. doi: 10.1021/jacs.0c05587
   PubMed Web of Science ®Google Scholar
• Kosar M, Sykes DA, Viray AEG, et al. Platform reagents enable synthesis of ligand-directed covalent probes: study of cannabinoid receptor 2 in live cells. J Am Chem Soc. 2023;145(28):15094–15108.
   PubMed Web of Science ®Google Scholar
• Kosar M, Sarott RC, Sykes DA, et al. Flipping the GPCR Switch: Structure-Based Development of Selective Cannabinoid Receptor 2 Inverse Agonists. ACS Cent Sci. 2024;10(5):956–968.
   PubMed Web of Science ®Google Scholar
• Morales P, Goya P, Jagerovic N. Emerging strategies targeting CB(2) cannabinoid receptor: biased agonism and allosterism. Biochem Pharmacol. 2018 Nov;157:8–17. doi: 10.1016/j.bcp.2018.07.031
   PubMed Web of Science ®Google Scholar
• Martella A, Sijben H, Rufer AC, et al. A novel selective inverse agonist of the CB(2) receptor as a radiolabeled tool compound for kinetic binding studies. Mol Pharmacol. 2017 Oct;92(4):389–400. doi: 10.1124/mol.117.108605
   PubMed Web of Science ®Google Scholar
• Omeara Jeffrey A, Pauls Heinz W, inventors; Canopy Growth Corp, assignee. Cannabinoid derivatives. WO patent WO 2021/007662 A1. 2021 [2020 Jul 10].
   Google Scholar